Welcome to our dedicated page for Bachem Holding news (Ticker: BCHMY), a resource for investors and traders seeking the latest updates and insights on Bachem Holding stock.
Bachem Holding AG (BCHMY) is a global leader in peptide and oligonucleotide manufacturing for pharmaceutical and biotechnology applications. This page provides investors and industry professionals with centralized access to official company announcements, including production expansions, research breakthroughs, and strategic partnerships.
Our curated news feed delivers timely updates on clinical development milestones, regulatory filings, and operational developments. Users will find detailed coverage of earnings reports, manufacturing capacity expansions, and innovations in therapeutic peptide technologies.
The resource features verified information about Bachem's global operations, quality management systems, and R&D initiatives. Content categories include production facility updates, pharmaceutical collaborations, and scientific advancements in oligonucleotide synthesis.
Bookmark this page for direct access to Bachem's latest developments in biopharmaceutical manufacturing. Check regularly for authoritative updates on the company's progress in meeting global healthcare demands through specialized chemical production.
Bachem (SIX: BANB) has announced that Dr. Simone Wyss Fedele will be recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2025. Dr. Wyss Fedele, currently CEO of Switzerland Global Enterprise (S-GE), brings extensive experience in the life science industry and international business.
Dr. Wyss Fedele's background includes leadership roles at Novartis International as Chief Economist and Head of Public Affairs, and at Takeda Pharmaceuticals as Commercial Lead and Head of Market Access for Europe and Canada. She holds positions on various prestigious boards, including the WEF Global Future Councils and the Swiss National Bank's Regional Council Northwest Switzerland.
All current board members will stand for re-election. The company has also announced key upcoming dates, including the dividend payout date on May 7, 2025, and the Half-Year Report 2025 publication on July 24, 2025.
Bachem (SIX: BANB) reported strong financial results for 2024, with group sales increasing 4.8% to CHF 605.3 million and EBITDA rising 5.7% to CHF 176.3 million. The company achieved an EBITDA margin of 29.1% and net income growth of 7.5% to CHF 120.2 million.
Sales performance across categories showed positive momentum: Commercial API sales grew 5.8% to CHF 327.0 million, CMC Development increased 3.0% to CHF 234.4 million, and Research & Specialties rose 7.5% to CHF 43.8 million.
The company invested CHF 292.2 million in capacity expansion in 2024, including progress on building 'K' in Bubendorf, set to begin test batch production in Q2 2025. Bachem targets 10-15% growth in local currencies for 2025, with planned CAPEX investments exceeding CHF 400 million. The company aims to achieve annual sales of over CHF 1 billion with an EBITDA margin above 30% by 2026.
Bachem Group (SIX: BANB) reported a slight sales growth of 0.2% to CHF 240.3 million in the first half of 2024, with a 1.3% increase in local currencies. EBITDA rose by 5.6% to CHF 55.5 million, with a margin of 23.1%. The company expects mid- to high-single-digit percentage growth in local currencies for 2024, maintaining a stable EBITDA margin. Bachem aims for annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026.
Sales in the Commercial API category declined by 13.4%, while CMC Development saw an 18.7% increase. The company is expanding production capacities globally, with significant investments across all sites. Bachem has begun commissioning equipment in its largest production plant for peptides and oligonucleotides in Bubendorf and is planning a new manufacturing site in Eiken.
